Long thought to be undruggable, Nurr1 is a nuclear receptor and transcription factor involved in the development, maintenance, and survival of midbrain dopaminergic neurons, which makes it an attractive target for developing therapeutics for such indications of Parkinson’s disease, multiple sclerosis, and schitzophrenia.
If validated, this could be the first therapeutic to target Nurr1 directly instead of any upstream effectors that control dopaminergic neurons.
Small molecule modulators of Nurr1 function may be used to :
UCSF scientists have conducted a screen which allowed them to identify chemical hits that bind the ligand-binding domain of Nurr1 with the long term goal of developing ligands that stabilize specific nuclear receptor conformations and regulate specific target genes.
To develop & commercialize the technology as a therapeutic for treating neurological diseases.
Proof of Concept
Available under CDA